Democrats such as Elizabeth Warren had their eye on business and the working class during the first 2020 presidential primary debate in Miami.2020 Electionsread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
The Chinese Ministry of Commerce maintained a firm stance against the U.S. during a weekly press conference on Thursday, less than two days ahead of a scheduled meeting...China Economyread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
The stock market is shrinking for several key reasons, but there's a way for investors to maneuver it, says Citi Research strategist Robert Buckland.Trading Nationread more
Credit Suisse initiated coverage of Tesla Wednesday with an "underperform" rating and a price target 15% below where the stock closed.Marketsread more
Something unusual is happening in financial markets, and it could mean more gains lie ahead for stocks, if history is any indication.Marketsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
The collapse of the deal potentially ended Sinclair's hopes of building a national conservative-leaning TV powerhouse that might have rivaled Fox News.Mediaread more
Mylan said on Tuesday it would recall certain batches of blood pressure medicine valsartan in the United States after they were found to contain a probable cancer-causing impurity, the latest recall amid heightened safety concerns globally.
Shares of the company, which on Tuesday also disclosed a warning letter it received from the FDA earlier this month, fell nearly 2 percent to $33.91 after the bell.
The news comes a day after the European Union authorities stepped in to effectively ban sales of valsartan made by an India-based Mylan unit after some batches were found to contain the same impurity, N-nitrosodiethylamine (NDEA).
Mylan said on Tuesday it would recall at least 15 lots of medicines containing valsartan distributed in the United States between March 2017 and November 2018 and manufactured by units Mylan Pharmaceuticals and Mylan Laboratories.
Over the past year, global health authorities have been cracking down on valsartan and drugs containing the substance as an active ingredient after several batches were found to contain NDEA and a second possible carcinogen, N-nitrosodimethylamine (NDMA).
The U.S. FDA last month halted imports of drug ingredients or medicines containing ingredients produced at a factory belonging to a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals.
Huahai had recalled the tainted product from consumers in the United States in July.